<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439971</url>
  </required_header>
  <id_info>
    <org_study_id>B3051001</org_study_id>
    <secondary_id>2011-002170-23</secondary_id>
    <nct_id>NCT01439971</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia</brief_title>
  <official_title>An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalyst Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalyst Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study hypothesizes that the study drug, PF-05280602 (at the selected doses) will be safe
      to administer to subjects with severe Hemophilia A or B with or without inhibitors and will
      demonstrate evidence of hemostatic activity. This is supported by the preclinical findings in
      hemophilic animal models.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The was an ascending dose trial with one open label treatment, intervention model was sequential dose escalation.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
    <description>Supine blood pressure (BP) was measured with the participant's arm supported at the level of the heart, and recorded to the nearest millimeters of mercury (mmHg) after 5 minutes of rest. The same arm (preferably the dominant arm) was to be used throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
    <description>Body temperature was measured by mouth (oral) or ear (tympanic). A temperature greater than 38.5 degree Celsius was considered a fever.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Respiration Rate</measure>
    <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
    <description>Respiration rate measured as respirations per minute (resp/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Supine Pulse Rate</measure>
    <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
    <description>Change from baseline is the vital sign value at Day 2, Day 3, and Day 15 minus vital sign value at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Changes Since Previous Physical Examination</measure>
    <time_frame>Baseline (Day 0), Day 1, Day 2, Day 3, Day 15</time_frame>
    <description>Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner. A complete physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, genitourinary, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>ECG findings of potential clinical concern were: PR interval greater than or equal to (&gt;=)300 milliseconds (msec), &gt;=25% increase from baseline for baseline values &gt;200 msec, &gt;=50% increase from baseline for baseline values less than or equal to (&lt;=)200 msec; QRS complex &gt;=140 msec or &gt;=50% increase from baseline; QTcF interval (Fridericia's correction) &gt;=450 msec or &gt;=30 msec increase from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs (Except Hemophilia AEs)</measure>
    <time_frame>Baseline through Day 60</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 15 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Hemophilia AEs and Withdrawals Due to Hemophilia AEs</measure>
    <time_frame>Baseline through Day 60</time_frame>
    <description>Hemophilia AEs included spontaneous (no known contributing factor) and traumatic (known or presumed contributing factor/reason) bleeding episodes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment-Emergent AEs and SAEs by Severity (Except Hemophilia AEs)</measure>
    <time_frame>Baseline through Day 60</time_frame>
    <description>AE severity were graded as mild, moderate, or severe. Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment-Emergent Hemophilia AEs by Severity</measure>
    <time_frame>Baseline through Day 60</time_frame>
    <description>Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Abnormal Troponin-T Levels by Magnitude</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>Troponin-T is a cardiac marker for the evaluation of possible cardiovascular injury. Troponin-T levels of potential clinical concern are values &gt;1.5 times the upper limit of normal (1.5X ULN) or &gt;=2.5X ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Abnormal Anti-Thrombin III (ATIII) Levels by Magnitude</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>ATIII is a protein in the blood that blocks abnormal blood clots from forming. Low levels of ATIII can cause abnormal blood clots. ATIII levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Abnormal Tissue Factor Pathway Inhibitor (TFPI) Levels by Magnitude</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>TFPI is a polypeptide that can regulate blood coagulation. TFPI levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Laboratory Test Abnormalities (Normal Baseline)</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelets, leukocytes, total neutrophils, eosinophils, basophils, lymphocytes, monocytes); chemistry (total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, creatinine, blood urea nitrogen [BUN], glucose, uric acid, sodium, potassium, chloride, bicarbonate, calcium, albumin, total protein, creatine kinase); urinalysis (urine white blood cell [WBC], urine RBC); other (troponin T).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities Meeting Stopping Criteria</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>Clinically significant findings for stopping rules are: hemoglobin &lt;8 grams/deciliter (g/dL) or &gt;20% decrease from normal baseline; WBC &gt;20,000 cells/mm^3 or &lt;1,500 decrease with normal baseline; platelets &lt;100,000/mm^3 or &gt;33% decrease from baseline; total bilirubin &gt;1.5X ULN; AST or ALT &gt;2.5X ULN; alkaline phosphatase &gt;3X ULN; creatinine &gt;1.5X baseline; BUN &gt;31.0 mg/dL; glucose &lt;0.6 or &gt;1.5X reference range; uric acid &gt; ULN; sodium &gt;150 or &lt;130 mEq/L; potassium &gt;5.5 or &lt;3.0 mEq/L; calcium &gt;11.5 or &lt;8.0 mg/dL; albumin &lt;2.0 g/L; total protein &lt;5.0 g/L; positive D-dimer at Day 15; PT prolonged by 3 seconds above baseline; ATIII &lt; LLN and &gt;20% decrease from baseline; troponin-T values above the reference range; fibrinogen &lt;0.75X LLN or &gt;25% decrease from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Immune Response (Anti-Drug Antibodies [ADA], PF-05280602 Inhibitor, Factor VIIa Inhibitor, Factor VII Inhibitor, and Depletion of Factor VII Activity)</measure>
    <time_frame>Baseline through Day 60</time_frame>
    <description>Assays for the determination of a positive immune response was performed. An antibody immune response was defined as a confirmed post-treatment positive ELISA result in combination with a negative baseline sample ELISA result. Positive antibody immune responses to PF-05280602 by ELISA was evaluated for cross reactivity to NovoSeven RT and to Factor VII.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IncRec)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>IncRec is the maximum rise in plasma concentration per administered dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>AUCinf is area under the plasma concentration-time curve from time 0 extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>MRT is AUMCinf/AUCinf, where AUMC is the area under the first moment curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose is influenced by the fraction of the dose absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Decrease From Baseline in Prothrombin Time (PT)</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>PT measures how long it takes blood to clot. Maximum mean decrease from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Decrease From Baseline in Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>aPTT is a blood test that characterizes blood coagulation. Maximum mean decrease from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Increase From Baseline in Thrombin Anti-Thrombin (TAT) Complexes</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>TAT complex is a parameter of coagulation and fibrinolysis. The normal reference range of values for TAT is 1 to 4.1 mcg/L. Elevated TAT concentrations may signify predisposition to thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Increase From Baseline in Prothrombin Fragments 1+2</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated Factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Increase From Baseline in D-Dimers</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>D-dimer is an indicator of fibrin formation and its subsequent lysis and is a useful biomarker representing overall activation of blood coagulation. Maximum mean increase from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Increase From Baseline in Endogenous Thrombin Potential (ETP)</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>ETP was evaluated using a Thrombin Generation Assay (TGA), a validated automated ex-vivo assay that measures the ability of plasma to generate thrombin. Thrombin generation curves are generated and calculated using dedicated software. ETP is the area under the thrombin generation curve and represents the total amount of generated thrombin. Maximum mean increase from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Decrease From Baseline in Thrombin Generation Lag Time</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>The lag time is defined as the time to reach one sixth of the peak height and is a measure of the initiation phase. It is equivalent to the clotting time. Maximum mean decrease from baseline at any time point was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Mean Increase From Baseline in Peak Thrombin Generation</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>The peak height is defined as the maximum thrombin concentration produced. Maximum mean increase from baseline at any time point was reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280602</intervention_name>
    <description>0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280602</intervention_name>
    <description>4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280602</intervention_name>
    <description>9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280602</intervention_name>
    <description>18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05280602</intervention_name>
    <description>30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects 18 to &lt;65 years old with severe hemophilia A or B with or without
             inhibitors to FVIII or FIX.

          -  Subjects is willing and able to comply with the mandatory washout periods prior to
             screening and prior to dosing and through 48 hours post dosing. At screening this
             includes a washout of FIX for 96 hours and FVIII for 72 houts. At dosing this includes
             a washout of FIX for 96 hours and FVIII and other hemostatic agents for 72 hours
             through 48 hours post dosing.

          -  Subjects must agree and commit to using a a highly effective method of birth control
             from the time of screening through four weeks after study drug administration.

        Exclusion Criteria:

          -  Presence of a bleeding disorder in addition to hemophilia A or B.

          -  Regular, concomitant therapy with immunomodulating drugs (eg, intravenous
             immunoglobulin, and routine systemic corticosteroids).

          -  History of coronary artery disease, thrombolic disease or diagnosis of prothrombic
             disorder.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Investigational Pharmacy</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Comprehensive Hemophilia Program - Center for Blood Disorders</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi Kar/ I.sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica 1-Centro Regionale per le Malattie del Sangue</name>
      <address>
        <city>Castelfranco Veneto (TV)</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Farmacia- Ospedale Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto - Treviso</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Emofilia e Trombosi &quot;Angelo Bianchi Bonomi&quot; U.O.S. Dipartimentale per la Diagnosi e la Terapi</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Farmacia Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Malattie Emorragiche e Trombotiche - Ematologia</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmacia Ospedaliera Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>08011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Pharma (Pty) Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hampstead NHS Trust, Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology Department</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester Universtiy Hospitals NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3051001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <results_first_submitted>October 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2017</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was an open-label study to characterize the single dose pharmacokinetics (PK), pharmacodynamics, safety, and tolerability of 5 intravenous dose levels of PF-05280602 (0.5, 4.5, 9.0, 18.0 and 30.0 micrograms/kilogram [mcg/kg]).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-05280602 0.5 mcg/kg</title>
          <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
        </group>
        <group group_id="P2">
          <title>PF-05280602 4.5 mcg/kg</title>
          <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>PF-05280602 9.0 mcg/kg</title>
          <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>PF-05280602 18.0 mcg/kg</title>
          <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>PF-05280602 30.0 mcg/kg</title>
          <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Required number in cohort dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population included all enrolled participants who received the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-05280602 0.5 mcg/kg</title>
          <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
        </group>
        <group group_id="B2">
          <title>PF-05280602 4.5 mcg/kg</title>
          <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>PF-05280602 9.0 mcg/kg</title>
          <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>PF-05280602 18.0 mcg/kg</title>
          <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>PF-05280602 30.0 mcg/kg</title>
          <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0">Single participant in cohort</measurement>
                    <measurement group_id="B2" value="32.7" spread="13.4"/>
                    <measurement group_id="B3" value="38.5" spread="12.1"/>
                    <measurement group_id="B4" value="32.8" spread="12.3"/>
                    <measurement group_id="B5" value="41.0" spread="15.7"/>
                    <measurement group_id="B6" value="37.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FEMALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Supine blood pressure (BP) was measured with the participant’s arm supported at the level of the heart, and recorded to the nearest millimeters of mercury (mmHg) after 5 minutes of rest. The same arm (preferably the dominant arm) was to be used throughout the study.</description>
        <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Supine blood pressure (BP) was measured with the participant’s arm supported at the level of the heart, and recorded to the nearest millimeters of mercury (mmHg) after 5 minutes of rest. The same arm (preferably the dominant arm) was to be used throughout the study.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="130.2" spread="7.14"/>
                    <measurement group_id="O3" value="120.2" spread="25.41"/>
                    <measurement group_id="O4" value="124.2" spread="7.68"/>
                    <measurement group_id="O5" value="125.5" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-8.7" spread="8.24"/>
                    <measurement group_id="O3" value="-0.2" spread="14.41"/>
                    <measurement group_id="O4" value="-3.0" spread="6.51"/>
                    <measurement group_id="O5" value="-1.5" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-7.0" spread="6.99"/>
                    <measurement group_id="O3" value="2.2" spread="19.30"/>
                    <measurement group_id="O4" value="-5.5" spread="7.66"/>
                    <measurement group_id="O5" value="0.0" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-5.5" spread="12.18"/>
                    <measurement group_id="O3" value="4.7" spread="18.00"/>
                    <measurement group_id="O4" value="-4.5" spread="14.92"/>
                    <measurement group_id="O5" value="1.8" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="73.7" spread="6.35"/>
                    <measurement group_id="O3" value="70.5" spread="10.97"/>
                    <measurement group_id="O4" value="75.8" spread="4.67"/>
                    <measurement group_id="O5" value="77.0" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-2.8" spread="6.43"/>
                    <measurement group_id="O3" value="2.7" spread="6.28"/>
                    <measurement group_id="O4" value="-0.8" spread="5.12"/>
                    <measurement group_id="O5" value="-3.3" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-6.5" spread="6.57"/>
                    <measurement group_id="O3" value="3.3" spread="6.56"/>
                    <measurement group_id="O4" value="-2.2" spread="8.11"/>
                    <measurement group_id="O5" value="4.3" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-3.5" spread="11.41"/>
                    <measurement group_id="O3" value="6.0" spread="13.11"/>
                    <measurement group_id="O4" value="-4.3" spread="11.15"/>
                    <measurement group_id="O5" value="-4.5" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Weight</title>
        <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="75.0" spread="12.65"/>
                    <measurement group_id="O3" value="78.7" spread="10.73"/>
                    <measurement group_id="O4" value="78.0" spread="11.31"/>
                    <measurement group_id="O5" value="73.4" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-1.0" spread="0.98"/>
                    <measurement group_id="O3" value="-0.6" spread="0.72"/>
                    <measurement group_id="O4" value="-0.8" spread="1.31"/>
                    <measurement group_id="O5" value="-0.4" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-0.6" spread="0.85"/>
                    <measurement group_id="O3" value="-0.5" spread="0.60"/>
                    <measurement group_id="O4" value="-0.8" spread="1.39"/>
                    <measurement group_id="O5" value="-0.3" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.4" spread="1.09"/>
                    <measurement group_id="O3" value="0.6" spread="1.55"/>
                    <measurement group_id="O4" value="0.6" spread="1.26"/>
                    <measurement group_id="O5" value="0.2" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Temperature</title>
        <description>Body temperature was measured by mouth (oral) or ear (tympanic). A temperature greater than 38.5 degree Celsius was considered a fever.</description>
        <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature</title>
          <description>Body temperature was measured by mouth (oral) or ear (tympanic). A temperature greater than 38.5 degree Celsius was considered a fever.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>degree Celcius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="36.5" spread="0.29"/>
                    <measurement group_id="O3" value="36.5" spread="0.34"/>
                    <measurement group_id="O4" value="36.6" spread="0.30"/>
                    <measurement group_id="O5" value="36.4" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-0.4" spread="0.62"/>
                    <measurement group_id="O3" value="-0.1" spread="0.30"/>
                    <measurement group_id="O4" value="0.1" spread="0.34"/>
                    <measurement group_id="O5" value="0.2" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-0.2" spread="0.60"/>
                    <measurement group_id="O3" value="0.1" spread="0.15"/>
                    <measurement group_id="O4" value="-0.0" spread="0.41"/>
                    <measurement group_id="O5" value="0.2" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.1" spread="0.39"/>
                    <measurement group_id="O3" value="0.1" spread="0.36"/>
                    <measurement group_id="O4" value="0.1" spread="0.24"/>
                    <measurement group_id="O5" value="0.2" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Respiration Rate</title>
        <description>Respiration rate measured as respirations per minute (resp/min).</description>
        <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiration Rate</title>
          <description>Respiration rate measured as respirations per minute (resp/min).</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>resp/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="15.0" spread="2.76"/>
                    <measurement group_id="O3" value="15.2" spread="2.04"/>
                    <measurement group_id="O4" value="15.7" spread="1.97"/>
                    <measurement group_id="O5" value="16.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.5" spread="1.76"/>
                    <measurement group_id="O3" value="0.3" spread="3.50"/>
                    <measurement group_id="O4" value="2.2" spread="2.56"/>
                    <measurement group_id="O5" value="0.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.2" spread="3.37"/>
                    <measurement group_id="O3" value="0.3" spread="3.50"/>
                    <measurement group_id="O4" value="1.7" spread="1.63"/>
                    <measurement group_id="O5" value="0.2" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.7" spread="4.32"/>
                    <measurement group_id="O3" value="-0.2" spread="2.14"/>
                    <measurement group_id="O4" value="1.2" spread="3.49"/>
                    <measurement group_id="O5" value="-0.3" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Supine Pulse Rate</title>
        <description>Change from baseline is the vital sign value at Day 2, Day 3, and Day 15 minus vital sign value at baseline.</description>
        <time_frame>Baseline, Day 2, Day 3, and Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Supine Pulse Rate</title>
          <description>Change from baseline is the vital sign value at Day 2, Day 3, and Day 15 minus vital sign value at baseline.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="64.8" spread="6.21"/>
                    <measurement group_id="O3" value="69.3" spread="10.65"/>
                    <measurement group_id="O4" value="60.7" spread="10.69"/>
                    <measurement group_id="O5" value="66.5" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-1.3" spread="3.56"/>
                    <measurement group_id="O3" value="3.7" spread="6.89"/>
                    <measurement group_id="O4" value="8.8" spread="7.88"/>
                    <measurement group_id="O5" value="2.0" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="1.3" spread="6.80"/>
                    <measurement group_id="O3" value="2.5" spread="7.89"/>
                    <measurement group_id="O4" value="10.7" spread="5.65"/>
                    <measurement group_id="O5" value="3.3" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="8.3" spread="12.68"/>
                    <measurement group_id="O3" value="4.5" spread="12.68"/>
                    <measurement group_id="O4" value="10.2" spread="12.22"/>
                    <measurement group_id="O5" value="3.0" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Changes Since Previous Physical Examination</title>
        <description>Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner. A complete physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, genitourinary, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.</description>
        <time_frame>Baseline (Day 0), Day 1, Day 2, Day 3, Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes Since Previous Physical Examination</title>
          <description>Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner. A complete physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, genitourinary, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed at Day 2 in this arm.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>ECG findings of potential clinical concern were: PR interval greater than or equal to (&gt;=)300 milliseconds (msec), &gt;=25% increase from baseline for baseline values &gt;200 msec, &gt;=50% increase from baseline for baseline values less than or equal to (&lt;=)200 msec; QRS complex &gt;=140 msec or &gt;=50% increase from baseline; QTcF interval (Fridericia's correction) &gt;=450 msec or &gt;=30 msec increase from baseline.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings</title>
          <description>ECG findings of potential clinical concern were: PR interval greater than or equal to (&gt;=)300 milliseconds (msec), &gt;=25% increase from baseline for baseline values &gt;200 msec, &gt;=50% increase from baseline for baseline values less than or equal to (&lt;=)200 msec; QRS complex &gt;=140 msec or &gt;=50% increase from baseline; QTcF interval (Fridericia's correction) &gt;=450 msec or &gt;=30 msec increase from baseline.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" spread="7.14"/>
                    <measurement group_id="O3" value="0" spread="25.41"/>
                    <measurement group_id="O4" value="0" spread="7.68"/>
                    <measurement group_id="O5" value="0" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex &gt;=140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval &gt;=450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval &gt;=25/50% Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Complex &gt;=50% Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval 30-&lt;60 msec Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval &gt;=60 msec Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs (Except Hemophilia AEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 15 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
        <time_frame>Baseline through Day 60</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs (Except Hemophilia AEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 15 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals Due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Hemophilia AEs and Withdrawals Due to Hemophilia AEs</title>
        <description>Hemophilia AEs included spontaneous (no known contributing factor) and traumatic (known or presumed contributing factor/reason) bleeding episodes.</description>
        <time_frame>Baseline through Day 60</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Hemophilia AEs and Withdrawals Due to Hemophilia AEs</title>
          <description>Hemophilia AEs included spontaneous (no known contributing factor) and traumatic (known or presumed contributing factor/reason) bleeding episodes.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemophilia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemophilia SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals Due to Hemophilia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment-Emergent AEs and SAEs by Severity (Except Hemophilia AEs)</title>
        <description>AE severity were graded as mild, moderate, or severe. Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
        <time_frame>Baseline through Day 60</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-Emergent AEs and SAEs by Severity (Except Hemophilia AEs)</title>
          <description>AE severity were graded as mild, moderate, or severe. Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment-Emergent Hemophilia AEs by Severity</title>
        <description>Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
        <time_frame>Baseline through Day 60</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-Emergent Hemophilia AEs by Severity</title>
          <description>Mild severity AEs do not interfere with the participant's usual function. Moderate AEs interfere to some extent with the participant's usual function. Severe AEs interfere significantly with the participant's usual function.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild Hemophilia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Hemophilia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hemophilia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Abnormal Troponin-T Levels by Magnitude</title>
        <description>Troponin-T is a cardiac marker for the evaluation of possible cardiovascular injury. Troponin-T levels of potential clinical concern are values &gt;1.5 times the upper limit of normal (1.5X ULN) or &gt;=2.5X ULN.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Abnormal Troponin-T Levels by Magnitude</title>
          <description>Troponin-T is a cardiac marker for the evaluation of possible cardiovascular injury. Troponin-T levels of potential clinical concern are values &gt;1.5 times the upper limit of normal (1.5X ULN) or &gt;=2.5X ULN.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;1X lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=2.5X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Abnormal Anti-Thrombin III (ATIII) Levels by Magnitude</title>
        <description>ATIII is a protein in the blood that blocks abnormal blood clots from forming. Low levels of ATIII can cause abnormal blood clots. ATIII levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Abnormal Anti-Thrombin III (ATIII) Levels by Magnitude</title>
          <description>ATIII is a protein in the blood that blocks abnormal blood clots from forming. Low levels of ATIII can cause abnormal blood clots. ATIII levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;1X LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Abnormal Tissue Factor Pathway Inhibitor (TFPI) Levels by Magnitude</title>
        <description>TFPI is a polypeptide that can regulate blood coagulation. TFPI levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Abnormal Tissue Factor Pathway Inhibitor (TFPI) Levels by Magnitude</title>
          <description>TFPI is a polypeptide that can regulate blood coagulation. TFPI levels of potential clinical concern are values &lt;1X LLN and &gt;1X ULN.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;1X LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Laboratory Test Abnormalities (Normal Baseline)</title>
        <description>The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelets, leukocytes, total neutrophils, eosinophils, basophils, lymphocytes, monocytes); chemistry (total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, creatinine, blood urea nitrogen [BUN], glucose, uric acid, sodium, potassium, chloride, bicarbonate, calcium, albumin, total protein, creatine kinase); urinalysis (urine white blood cell [WBC], urine RBC); other (troponin T).</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Laboratory Test Abnormalities (Normal Baseline)</title>
          <description>The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelets, leukocytes, total neutrophils, eosinophils, basophils, lymphocytes, monocytes); chemistry (total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, creatinine, blood urea nitrogen [BUN], glucose, uric acid, sodium, potassium, chloride, bicarbonate, calcium, albumin, total protein, creatine kinase); urinalysis (urine white blood cell [WBC], urine RBC); other (troponin T).</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities Meeting Stopping Criteria</title>
        <description>Clinically significant findings for stopping rules are: hemoglobin &lt;8 grams/deciliter (g/dL) or &gt;20% decrease from normal baseline; WBC &gt;20,000 cells/mm^3 or &lt;1,500 decrease with normal baseline; platelets &lt;100,000/mm^3 or &gt;33% decrease from baseline; total bilirubin &gt;1.5X ULN; AST or ALT &gt;2.5X ULN; alkaline phosphatase &gt;3X ULN; creatinine &gt;1.5X baseline; BUN &gt;31.0 mg/dL; glucose &lt;0.6 or &gt;1.5X reference range; uric acid &gt; ULN; sodium &gt;150 or &lt;130 mEq/L; potassium &gt;5.5 or &lt;3.0 mEq/L; calcium &gt;11.5 or &lt;8.0 mg/dL; albumin &lt;2.0 g/L; total protein &lt;5.0 g/L; positive D-dimer at Day 15; PT prolonged by 3 seconds above baseline; ATIII &lt; LLN and &gt;20% decrease from baseline; troponin-T values above the reference range; fibrinogen &lt;0.75X LLN or &gt;25% decrease from baseline.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities Meeting Stopping Criteria</title>
          <description>Clinically significant findings for stopping rules are: hemoglobin &lt;8 grams/deciliter (g/dL) or &gt;20% decrease from normal baseline; WBC &gt;20,000 cells/mm^3 or &lt;1,500 decrease with normal baseline; platelets &lt;100,000/mm^3 or &gt;33% decrease from baseline; total bilirubin &gt;1.5X ULN; AST or ALT &gt;2.5X ULN; alkaline phosphatase &gt;3X ULN; creatinine &gt;1.5X baseline; BUN &gt;31.0 mg/dL; glucose &lt;0.6 or &gt;1.5X reference range; uric acid &gt; ULN; sodium &gt;150 or &lt;130 mEq/L; potassium &gt;5.5 or &lt;3.0 mEq/L; calcium &gt;11.5 or &lt;8.0 mg/dL; albumin &lt;2.0 g/L; total protein &lt;5.0 g/L; positive D-dimer at Day 15; PT prolonged by 3 seconds above baseline; ATIII &lt; LLN and &gt;20% decrease from baseline; troponin-T values above the reference range; fibrinogen &lt;0.75X LLN or &gt;25% decrease from baseline.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Thrombin III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-Dimer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Positive Immune Response (Anti-Drug Antibodies [ADA], PF-05280602 Inhibitor, Factor VIIa Inhibitor, Factor VII Inhibitor, and Depletion of Factor VII Activity)</title>
        <description>Assays for the determination of a positive immune response was performed. An antibody immune response was defined as a confirmed post-treatment positive ELISA result in combination with a negative baseline sample ELISA result. Positive antibody immune responses to PF-05280602 by ELISA was evaluated for cross reactivity to NovoSeven RT and to Factor VII.</description>
        <time_frame>Baseline through Day 60</time_frame>
        <population>The immunogenicity parameter population included enrolled and treated participants with at least 1 post-treatment anti-PF-05280602 antibody (ADA), PF-05280602 inhibitor, or Factor VII activity level determination.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Immune Response (Anti-Drug Antibodies [ADA], PF-05280602 Inhibitor, Factor VIIa Inhibitor, Factor VII Inhibitor, and Depletion of Factor VII Activity)</title>
          <description>Assays for the determination of a positive immune response was performed. An antibody immune response was defined as a confirmed post-treatment positive ELISA result in combination with a negative baseline sample ELISA result. Positive antibody immune responses to PF-05280602 by ELISA was evaluated for cross reactivity to NovoSeven RT and to Factor VII.</description>
          <population>The immunogenicity parameter population included enrolled and treated participants with at least 1 post-treatment anti-PF-05280602 antibody (ADA), PF-05280602 inhibitor, or Factor VII activity level determination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF-05280602 Inhibitor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor VIIa Inhibitor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor VII Inhibitor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depletion of Factor VII Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68">As only 1 participant was analyzed, geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O2" value="84.78" spread="20"/>
                    <measurement group_id="O3" value="183.1" spread="28"/>
                    <measurement group_id="O4" value="496.2" spread="14"/>
                    <measurement group_id="O5" value="814.8" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82">As only 1 participant was analyzed, geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O2" value="300.7" spread="15"/>
                    <measurement group_id="O3" value="638.9" spread="21"/>
                    <measurement group_id="O4" value="1557" spread="19"/>
                    <measurement group_id="O5" value="2788" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (t1/2)</title>
        <description>t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2)</title>
          <description>t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to low PF-05280602 levels, terminal phase was not well characterized.</measurement>
                    <measurement group_id="O2" value="3.533" spread="0.560"/>
                    <measurement group_id="O3" value="3.637" spread="0.803"/>
                    <measurement group_id="O4" value="3.303" spread="0.638"/>
                    <measurement group_id="O5" value="3.580" spread="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery (IncRec)</title>
        <description>IncRec is the maximum rise in plasma concentration per administered dose.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery (IncRec)</title>
          <description>IncRec is the maximum rise in plasma concentration per administered dose.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>ng/mL/mcg/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48">As only 1 participant was analyzed, geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O2" value="18.49" spread="20"/>
                    <measurement group_id="O3" value="20.06" spread="28"/>
                    <measurement group_id="O4" value="27.67" spread="16"/>
                    <measurement group_id="O5" value="26.87" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</title>
        <description>AUCinf is area under the plasma concentration-time curve from time 0 extrapolated to infinite time.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</title>
          <description>AUCinf is area under the plasma concentration-time curve from time 0 extrapolated to infinite time.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to low PF-05280602 levels, terminal phase was not well characterized.</measurement>
                    <measurement group_id="O2" value="300.7" spread="15"/>
                    <measurement group_id="O3" value="638.9" spread="21"/>
                    <measurement group_id="O4" value="1557" spread="19"/>
                    <measurement group_id="O5" value="2788" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)</title>
        <description>MRT is AUMCinf/AUCinf, where AUMC is the area under the first moment curve.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)</title>
          <description>MRT is AUMCinf/AUCinf, where AUMC is the area under the first moment curve.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to low PF-05280602 levels, terminal phase was not well characterized.</measurement>
                    <measurement group_id="O2" value="7.948" spread="1.786"/>
                    <measurement group_id="O3" value="5.697" spread="0.727"/>
                    <measurement group_id="O4" value="4.963" spread="0.741"/>
                    <measurement group_id="O5" value="5.087" spread="0.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss)</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss)</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>L/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to low PF-05280602 levels, terminal phase was not well characterized.</measurement>
                    <measurement group_id="O2" value="0.1168" spread="35"/>
                    <measurement group_id="O3" value="0.08060" spread="24"/>
                    <measurement group_id="O4" value="0.05651" spread="21"/>
                    <measurement group_id="O5" value="0.05494" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL)</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose is influenced by the fraction of the dose absorbed.</description>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose is influenced by the fraction of the dose absorbed.</description>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>L/hr/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to low PF-05280602 levels, terminal phase was not well characterized.</measurement>
                    <measurement group_id="O2" value="0.01502" spread="15"/>
                    <measurement group_id="O3" value="0.01423" spread="21"/>
                    <measurement group_id="O4" value="0.01149" spread="20"/>
                    <measurement group_id="O5" value="0.01089" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>Day 1 (pre-dose and 5 min, 10 min, 20 min, 30 min, 1 hr, 3 hr, 6 hr, 9 hr, and 12 hrs post-dose), Day 2 (24 hrs post-dose), Day 3 (48 hrs post-dose)</time_frame>
        <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>The PK parameter analysis population included enrolled and treated participants who had at least 1 of the PK parameters of interest.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" lower_limit="0.167" upper_limit="0.167"/>
                    <measurement group_id="O2" value="0.167" spread="15" lower_limit="0.083" upper_limit="0.200"/>
                    <measurement group_id="O3" value="0.242" spread="21" lower_limit="0.117" upper_limit="0.367"/>
                    <measurement group_id="O4" value="0.142" spread="20" lower_limit="0.083" upper_limit="0.333"/>
                    <measurement group_id="O5" value="0.150" spread="31" lower_limit="0.083" upper_limit="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Decrease From Baseline in Prothrombin Time (PT)</title>
        <description>PT measures how long it takes blood to clot. Maximum mean decrease from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Decrease From Baseline in Prothrombin Time (PT)</title>
          <description>PT measures how long it takes blood to clot. Maximum mean decrease from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-3.37" spread="0.372"/>
                    <measurement group_id="O3" value="-3.80" spread="0.629"/>
                    <measurement group_id="O4" value="-3.85" spread="0.409"/>
                    <measurement group_id="O5" value="-4.45" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Decrease From Baseline in Activated Partial Thromboplastin Time (aPTT)</title>
        <description>aPTT is a blood test that characterizes blood coagulation. Maximum mean decrease from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Decrease From Baseline in Activated Partial Thromboplastin Time (aPTT)</title>
          <description>aPTT is a blood test that characterizes blood coagulation. Maximum mean decrease from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-17.93" spread="8.944"/>
                    <measurement group_id="O3" value="-24.47" spread="12.273"/>
                    <measurement group_id="O4" value="-43.02" spread="16.541"/>
                    <measurement group_id="O5" value="-46.85" spread="12.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Increase From Baseline in Thrombin Anti-Thrombin (TAT) Complexes</title>
        <description>TAT complex is a parameter of coagulation and fibrinolysis. The normal reference range of values for TAT is 1 to 4.1 mcg/L. Elevated TAT concentrations may signify predisposition to thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Increase From Baseline in Thrombin Anti-Thrombin (TAT) Complexes</title>
          <description>TAT complex is a parameter of coagulation and fibrinolysis. The normal reference range of values for TAT is 1 to 4.1 mcg/L. Elevated TAT concentrations may signify predisposition to thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="23.82" spread="51.130"/>
                    <measurement group_id="O3" value="4.72" spread="5.282"/>
                    <measurement group_id="O4" value="5.52" spread="6.530"/>
                    <measurement group_id="O5" value="22.47" spread="28.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Increase From Baseline in Prothrombin Fragments 1+2</title>
        <description>Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated Factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Increase From Baseline in Prothrombin Fragments 1+2</title>
          <description>Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated Factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis. Maximum mean increase from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
          <units>picomoles per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="31.8" spread="30.56"/>
                    <measurement group_id="O3" value="66.4" spread="84.73"/>
                    <measurement group_id="O4" value="76.7" spread="28.27"/>
                    <measurement group_id="O5" value="238.3" spread="162.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Increase From Baseline in D-Dimers</title>
        <description>D-dimer is an indicator of fibrin formation and its subsequent lysis and is a useful biomarker representing overall activation of blood coagulation. Maximum mean increase from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 15</time_frame>
        <population>The safety population included all enrolled participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Increase From Baseline in D-Dimers</title>
          <description>D-dimer is an indicator of fibrin formation and its subsequent lysis and is a useful biomarker representing overall activation of blood coagulation. Maximum mean increase from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.0">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="75.0" spread="103.68"/>
                    <measurement group_id="O3" value="28.3" spread="173.60"/>
                    <measurement group_id="O4" value="88.3" spread="123.36"/>
                    <measurement group_id="O5" value="238.3" spread="285.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Increase From Baseline in Endogenous Thrombin Potential (ETP)</title>
        <description>ETP was evaluated using a Thrombin Generation Assay (TGA), a validated automated ex-vivo assay that measures the ability of plasma to generate thrombin. Thrombin generation curves are generated and calculated using dedicated software. ETP is the area under the thrombin generation curve and represents the total amount of generated thrombin. Maximum mean increase from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Increase From Baseline in Endogenous Thrombin Potential (ETP)</title>
          <description>ETP was evaluated using a Thrombin Generation Assay (TGA), a validated automated ex-vivo assay that measures the ability of plasma to generate thrombin. Thrombin generation curves are generated and calculated using dedicated software. ETP is the area under the thrombin generation curve and represents the total amount of generated thrombin. Maximum mean increase from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
          <units>nanomolar*minute (nM*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.400">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="212.643" spread="77.3337"/>
                    <measurement group_id="O3" value="186.196" spread="147.6925"/>
                    <measurement group_id="O4" value="287.173" spread="421.1883"/>
                    <measurement group_id="O5" value="522.758" spread="94.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Decrease From Baseline in Thrombin Generation Lag Time</title>
        <description>The lag time is defined as the time to reach one sixth of the peak height and is a measure of the initiation phase. It is equivalent to the clotting time. Maximum mean decrease from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Decrease From Baseline in Thrombin Generation Lag Time</title>
          <description>The lag time is defined as the time to reach one sixth of the peak height and is a measure of the initiation phase. It is equivalent to the clotting time. Maximum mean decrease from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.540">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="-6.235" spread="5.7141"/>
                    <measurement group_id="O3" value="-7.088" spread="7.9294"/>
                    <measurement group_id="O4" value="-13.400" spread="14.6902"/>
                    <measurement group_id="O5" value="-2.425" spread="0.9507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Mean Increase From Baseline in Peak Thrombin Generation</title>
        <description>The peak height is defined as the maximum thrombin concentration produced. Maximum mean increase from baseline at any time point was reported.</description>
        <time_frame>Baseline through Day 3</time_frame>
        <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05280602 0.5 mcg/kg</title>
            <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PF-05280602 4.5 mcg/kg</title>
            <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-05280602 9.0 mcg/kg</title>
            <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-05280602 18.0 mcg/kg</title>
            <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-05280602 30.0 mcg/kg</title>
            <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Mean Increase From Baseline in Peak Thrombin Generation</title>
          <description>The peak height is defined as the maximum thrombin concentration produced. Maximum mean increase from baseline at any time point was reported.</description>
          <population>The safety population included all enrolled participants who received the study drug. The 'Number of Participants Analyzed' is the number of evaluable participants for this measure.</population>
          <units>Nanomolar (nM)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.620">As only 1 participant was analyzed, standard deviation was not calculated.</measurement>
                    <measurement group_id="O2" value="17.982" spread="6.0924"/>
                    <measurement group_id="O3" value="16.568" spread="12.9124"/>
                    <measurement group_id="O4" value="23.362" spread="28.4618"/>
                    <measurement group_id="O5" value="49.130" spread="21.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 28 days after last study drug administration (Day 60)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PF-05280602 0.5 mcg/kg</title>
          <description>PF-05280602 0.5 mcg/kg, the original lowest dosing arm, was administered as a single dose of bolus intravenous infusion on Day 1. The protocol was amended after a single participant was enrolled and the starting dose was changed to 4.5 mcg/kg.</description>
        </group>
        <group group_id="E2">
          <title>PF-05280602 4.5 mcg/kg</title>
          <description>PF-05280602 4.5 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>PF-05280602 9.0 mcg/kg</title>
          <description>PF-05280602 9.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>PF-05280602 18.0 mcg/kg</title>
          <description>PF-05280602 18.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>PF-05280602 30.0 mcg/kg</title>
          <description>PF-05280602 30.0 mcg/kg was administered as a single dose of bolus intravenous infusion on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Catalyst Biosciences has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The protocol was amended to a starting dose of 4.5 mcg/kg. The positive anti-PF-05280602 antibody was cross-reactive with NovoSeven and native Factor VII and the weak positive immune response at Day 60 may represent a false-positive test result.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Catalyst Biosciences</organization>
      <phone>1-650-266-8671</phone>
      <email>hlevy@catbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

